These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 34918885)

  • 1. Impact of sacubitril/valsartan on systolic heart failure: Right heart location and clustering analysis.
    Bouali Y; Galli E; Paven E; Laurin C; Arnaud H; Oger E; Donal E
    Adv Clin Exp Med; 2022 Feb; 31(2):109-119. PubMed ID: 34918885
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sacubitril/Valsartan in the Treatment of Right Ventricular Dysfunction in Patients With Heart Failure With Reduced Ejection Fraction: A Real-world Study.
    Yang Y; Shen C; Lu J; Fu G; Xiong C
    J Cardiovasc Pharmacol; 2022 Feb; 79(2):177-182. PubMed ID: 34711748
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of angiotensin receptor neprilysin inhibition on pulmonary arterial stiffness in heart failure with reduced ejection fraction.
    Yenerçağ M; Arslan U; Dereli S; Çoksevim M; Doğduş M; Kaya A
    Int J Cardiovasc Imaging; 2021 Jan; 37(1):165-173. PubMed ID: 32815051
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Left ventricular reverse remodeling following initiation of sacubitril/valsartan for heart failure with reduced ejection fraction and low blood pressure.
    Nishihara Y; Nishimori M; Sawa T; Uemura K; Nagai S; Todo S; Oota E; Odajima S; Takeuchi K; Ichikawa Y; Kintsu M; Yamauchi Y; Shiraki H; Yamashita K; Fukuda T; Hisamatsu E; Shimizu M; Hirata KI; Tanaka H
    Heart Vessels; 2024 Feb; 39(2):95-104. PubMed ID: 37733071
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictors of right ventricular function improvement with sacubitril/valsartan in a real-life population of patients with chronic heart failure.
    Correale M; Mazzeo P; Magnesa M; Fortunato M; Tricarico L; Leopizzi A; Mallardi A; Mennella R; Tucci S; Brunetti ND
    Clin Physiol Funct Imaging; 2021 Nov; 41(6):505-513. PubMed ID: 34510702
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of Sacubitril/Valsartan Compared With Ramipril on Cardiac Structure and Function After Acute Myocardial Infarction: The PARADISE-MI Echocardiographic Substudy.
    Shah AM; Claggett B; Prasad N; Li G; Volquez M; Jering K; Cikes M; Kovacs A; Mullens W; Nicolau JC; Køber L; van der Meer P; Jhund PS; Ibram G; Lefkowitz M; Zhou Y; Solomon SD; Pfeffer MA
    Circulation; 2022 Oct; 146(14):1067-1081. PubMed ID: 36082663
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The reverse remodeling response to sacubitril/valsartan therapy in heart failure with reduced ejection fraction.
    Martens P; Beliën H; Dupont M; Vandervoort P; Mullens W
    Cardiovasc Ther; 2018 Aug; 36(4):e12435. PubMed ID: 29771478
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of sacubitril/valsartan on echo parameters in heart failure patients with reduced ejection fraction a prospective evaluation.
    Bayard G; Da Costa A; Pierrard R; Roméyer-Bouchard C; Guichard JB; Isaaz K
    Int J Cardiol Heart Vasc; 2019 Dec; 25():100418. PubMed ID: 31517034
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessment of sacubitril/valsartan effects on left ventricular dynamics using 3D echocardiography and 3D strain in heart failure with reduced ejection fraction patients.
    Öz TK; Abdelnabi M; Fiore C; Almaghraby A; Cihan D; Babazade N; Haseeb Raza Naqvi S; Omar B; Dağdeviren B
    Minerva Cardiol Angiol; 2022 Aug; 70(4):431-438. PubMed ID: 34713680
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of Sacubitril/Valsartan on the Right Ventricular Function and Pulmonary Hypertension in Patients With Heart Failure With Reduced Ejection Fraction: A Systematic Review and Meta-Analysis of Observational Studies.
    Zhang J; Du L; Qin X; Guo X
    J Am Heart Assoc; 2022 May; 11(9):e024449. PubMed ID: 35470677
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of β-blocker therapy on right ventricular function in heart failure patients with reduced ejection fraction. A prospective evaluation.
    Galves R; Da Costa A; Pierrard R; Bayard G; Guichard JB; Isaaz K
    Echocardiography; 2020 Sep; 37(9):1392-1398. PubMed ID: 32815195
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sacubitril/valsartan improves cardiac function in Chinese patients with heart failure: a real-world study.
    Chen W; Liu Y; Li Y; Dang H
    ESC Heart Fail; 2021 Oct; 8(5):3783-3790. PubMed ID: 34155812
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reverse Cardiac Remodeling Following Initiation of Sacubitril/Valsartan in Patients With Heart Failure With and Without Diabetes.
    Khan MS; Felker GM; Piña IL; Camacho A; Bapat D; Ibrahim NE; Maisel AS; Prescott MF; Ward JH; Solomon SD; Januzzi JL; Butler J
    JACC Heart Fail; 2021 Feb; 9(2):137-145. PubMed ID: 33309581
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sacubitril/Valsartan in Patients With Heart Failure and Concomitant End-Stage Kidney Disease.
    Niu CY; Yang SF; Ou SM; Wu CH; Huang PH; Hung CL; Lin CC; Li SY
    J Am Heart Assoc; 2022 Sep; 11(18):e026407. PubMed ID: 36062622
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of Sacubitril/Valsartan on cardiac function and cardiac remodeling in patients with heart failure with reduced ejection fraction.
    Chen F; Tian G; Bai X; Li J; Yuan Z
    Ann Palliat Med; 2021 Aug; 10(8):8684-8691. PubMed ID: 34488357
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The comparative effects of sacubitril/valsartan versus enalapril on pulmonary hypertension due to heart failure with a reduced ejection fraction.
    Zhao Y; Tian LG; Zhang LX; Ma T; Di L; Wang YB; Gu XS; Wang DD; Gao S; Wang H
    Pulm Circ; 2022 Jul; 12(3):e12034. PubMed ID: 35874853
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of sacubitril/valsartan on implantable defibrillator eligibility in heart failure: a real-world experience.
    Monzo L; Gaudio C; Cicogna F; Tota C; Petronilli V; Mennuni S; De Ruvo E; Calò L
    Eur Rev Med Pharmacol Sci; 2021 Sep; 25(18):5690-5700. PubMed ID: 34604961
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of SAcubitril/Valsartan on left vEntricular ejection fraction and on the potential indication for Implantable Cardioverter Defibrillator in primary prevention: the SAVE-ICD study.
    Guerra F; Ammendola E; Ziacchi M; Aspromonte V; Pellegrino PL; Del Giorno G; Dell'Era G; Pimpini L; Santoro F; Floris R; Stronati G; Nigro G; Paolisso P; Guido A; Maglia G; Brunetti ND; Carbone A; Gravellone M; Antonicelli R; Cannone M; Accogli M; Dello Russo A; Palmisano P
    Eur J Clin Pharmacol; 2021 Dec; 77(12):1835-1842. PubMed ID: 34279677
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Our Experience With Sacubitril/Valsartan in Chronic Heart Failure Management - HFrEF in the Ambulatory Setting.
    Naser N; Kulić M; Jatić Z
    Med Arch; 2022 Apr; 76(2):101-107. PubMed ID: 35774049
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reverse Remodeling Effects of Sacubitril-Valsartan: Structural and Functional Optimization in Stage C Heart Failure.
    Kalanatari S; Oren D; Medvedofsky D; Narang A; Imamura T; Tayazime S; Kim GH; Raikhelkar J; Sayer G; Lang RM; Uriel N
    Am J Cardiol; 2024 Jan; 210():249-255. PubMed ID: 37884115
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.